STAT3 Inhibitor and Checkpoint Blockade Combination Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pancreatic ductal adenocarcinoma (PDAC) has limited treatment options, with single agent immune checkpoint inhibitors being ineffective due to a complex tumor microenvironment that suppresses anti-tumor immunity, necessitating a strategy to enhance immunotherapy efficacy.
Innovation Solution
Combining a STAT3 inhibitor, such as WP1066 or WP1732, with one or more immune checkpoint inhibitors like anti-PD1, anti-PD-L1, or anti-CTLA-4 therapies to overcome immune suppression and promote anti-tumor responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single agent immune checkpoint inhibitors are used, then treatment simplicity is maintained, but therapeutic efficacy is insufficient due to tumor microenvironment immune suppression
Solution Approach 1:
The patent combines a STAT3 inhibitor with immune checkpoint inhibitors to create a combination therapy regimen. This merging of multiple therapeutic agents addresses the insufficient efficacy of single-agent immune checkpoint inhibitors by simultaneously targeting both STAT3 signaling pathway and immune checkpoint molecules, thereby overcoming tumor microenvironment-mediated immune suppression while maintaining a manageable treatment protocol
2Reliability
If combination therapy with STAT3 inhibitor and immune checkpoint inhibitor is used, then anti-tumor immune response is enhanced, but treatment complexity increases
Solution Approach 1:
The combination therapy is administered in a segmented manner with specific dosing schedules where the STAT3 inhibitor and immune checkpoint inhibitor are given at different times and frequencies. This segmentation of the treatment protocol allows each agent to be optimized independently while reducing the burden of simultaneous administration, thereby enhancing anti-tumor immune response without overwhelming treatment complexity
3Reliability
If STAT3 inhibitor is added to immune checkpoint inhibitor therapy, then immune suppression is reduced, but treatment cost and administration burden increase
Solution Approach 1:
The treatment protocol employs periodic administration where the STAT3 inhibitor is given on specific days (e.g., days 1, 8, 15) while the immune checkpoint inhibitor is administered on different schedules. This periodic action pattern reduces the cumulative administration burden compared to continuous daily dosing of both agents, while maintaining sustained reduction of immune suppression through consistent STAT3 inhibition
Data Source
AI summary
Provided herein are methods of treating patients with a combination of a transcription inhibitor (e.g., a STAT3 inhibitor) and an immune checkpoint blockade therapy (e.g., anti-PD-1 therapy, anti-PD-L1 therapy, anti-CTLA-4 therapy). The patient may have a proliferative disease, such as cancer or psoriasis. The patient may have a pathogenic infection.